AmbioPharm

AmbioPharm, Inc. (APi) has developed a new business model responsive to an accelerating trend in our industry

AmbioPharm, Inc. (APi) has developed a new business model responsive to an accelerating trend in our industry to drive down costs of manufacturing peptides. We are looking forward to becoming your manufacturing partner for your peptide projects from preclinical and clinical to commercial. Please allow us to introduce APi’s capabilities. We have established a new custom peptide supply service designed to manufacture peptides rapidly and at the lowest possible cost for pharmaceutical and biotech companies. At your request, we will provide research-grade peptides for your pre-clinical in-vitro, medicinal and toxicology programs. This service will provide you with milligrams to multi-grams of research-grade peptides fully-qualified and released by our in-house Quality Control Department. We can perform solid-phase, solution-phase or hybrid peptide chemistry plus organic conjugations to proteins, toxoids, antifungals, KLH, and PEG .